0000950170-23-007304.txt : 20230310 0000950170-23-007304.hdr.sgml : 20230310 20230310162733 ACCESSION NUMBER: 0000950170-23-007304 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230307 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20230310 DATE AS OF CHANGE: 20230310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Biopharma, Inc. CENTRAL INDEX KEY: 0001645460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473324577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38327 FILM NUMBER: 23724054 BUSINESS ADDRESS: STREET 1: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-949-2680 MAIL ADDRESS: STREET 1: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: Imagen Biopharma, Inc. DATE OF NAME CHANGE: 20150617 8-K 1 cue-20230307.htm 8-K 8-K
0001645460false00016454602023-03-072023-03-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 7, 2023

 

Cue Biopharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

Delaware

 

001-38327

 

47-3324577

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

 

40 Guest Street

Boston, Massachusetts

 

02135

(Zip Code)

(Address of principal executive offices)

 

 

 

(617) 949-2680

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.001 per share

 

CUE

 

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

IF " DOCVARIABLE "SWDocIDLocation" 1" = "1" " DOCPROPERTY "SWDocID" ActiveUS 198232452v.1" "" ActiveUS 198232452v.1

 

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

IF " DOCVARIABLE "SWDocIDLocation" 1" = "1" " DOCPROPERTY "SWDocID" ActiveUS 198232452v.1" "" ActiveUS 198232452v.1

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

 

 

On March 7, 2023, Ms. Howson informed the Board of Directors of Cue Biopharma, Inc. (the “Company”) of her intent to retire from the Board of Directors and not stand for re-election at the Company’s 2023 annual meeting of stockholders (the “2023 Annual Meeting”). Ms. Howson’s decision to retire from the Board of Directors and not stand for re-election did not involve any disagreement on any matter relating to the Company’s operations, policies or practices. Ms. Howson will continue to serve as a director until the 2023 Annual Meeting. Ms. Howson is a member of the Compensation Committee and the Corporate Governance and Nominating Committee.

 

 

IF " DOCVARIABLE "SWDocIDLocation" 1" = "1" " DOCPROPERTY "SWDocID" ActiveUS 198232452v.1" "" ActiveUS 198232452v.1

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

Cue Biopharma, Inc.

 

 

 

 

Date: March 10, 2023

 

 

 

By:

 

/s/ Daniel R. Passeri

 

 

 

 

Name: Daniel R. Passeri

 

 

 

 

Title: Chief Executive Officer

 

 

IF " DOCVARIABLE "SWDocIDLocation" 1" = "1" " DOCPROPERTY "SWDocID" ActiveUS 198232452v.1" "" ActiveUS 198232452v.1

 EX-101.PRE 2 cue-20230307_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 3 cue-20230307_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Soliciting Material Amendment Flag Entity Addresses, Address Type [Axis] Entity Incorporation, State or Country Code City Area Code Document Period End Date Entity Address, Postal Zip Code Securities Act File Number Entity Address, Address Line One Address Type [Domain] Entity Tax Identification Number Entity Emerging Growth Company Document Information [Line Items] Entity Registrant Name Pre-commencement Tender Offer Title of 12(b) Security Entity Address, State or Province Document Type Written Communications Security Exchange Name Entity Address, Address Line Two Entity Central Index Key Former Address [Member] Document Information [Table] Local Phone Number Pre-commencement Issuer Tender Offer Cover [Abstract] Trading Symbol EX-101.SCH 4 cue-20230307.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 cue-20230307_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Mar. 07, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 07, 2023
Entity Registrant Name Cue Biopharma, Inc.
Entity Central Index Key 0001645460
Entity Emerging Growth Company false
Securities Act File Number 001-38327
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-3324577
Entity Address, Address Line One 40 Guest Street
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02135
City Area Code 617
Local Phone Number 949-2680
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CUE
Security Exchange Name NASDAQ
XML 7 cue-20230307_htm.xml IDEA: XBRL DOCUMENT 0001645460 2023-03-07 2023-03-07 0001645460 false 8-K 2023-03-07 Cue Biopharma, Inc. DE 001-38327 47-3324577 40 Guest Street Boston MA 02135 617 949-2680 false false false false Common Stock, par value $0.001 per share CUE NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports cue-20230307.htm cue-20230307.xsd cue-20230307_def.xml cue-20230307_lab.xml cue-20230307_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cue-20230307.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "cue-20230307_def.xml" ] }, "inline": { "local": [ "cue-20230307.htm" ] }, "labelLink": { "local": [ "cue-20230307_lab.xml" ] }, "presentationLink": { "local": [ "cue-20230307_pre.xml" ] }, "schema": { "local": [ "cue-20230307.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cue", "nsuri": "http://www.cuebiopharma.com/20230307", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cue-20230307.htm", "contextRef": "C_9f080b0e-34f6-4e14-89b5-abf891d2cc82", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cue-20230307.htm", "contextRef": "C_9f080b0e-34f6-4e14-89b5-abf891d2cc82", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r6", "r7" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cuebiopharma.com/20230307/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-007304-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-007304-xbrl.zip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end